AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21184272
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg/day (n=21)
Trial: 21184272
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (n=16)
Trial: 18199893
Drug: Piperaquine phosphate
RxNorm normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Piperaquine phosphate 500 mg
Trial: 18199893
Drug: Piperaquine phosphate
RxNorm normalized name: Piperaquine phosphate
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Piperaquine phosphate 750 mg
Trial: 10587839
Drug: Ethanol infusion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol infusion (4.35 mmol.kg‐1.h‐1)
Trial: 29712745
Drug: Intensive systolic
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systolic blood pressure treatment
Trial: 29712745
Drug: Standard systolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard systolic blood pressure treatment
Trial: 21404147
Drug: Alprazolam sublingual
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam sublingual tablets (ALP-SL)
Trial: 17303799
Drug: vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin (50 mg b.i.d.)
Trial: 14648339
Drug: Combined low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined low-dose enalapril
Trial: 11409580
Drug: amikacin 5
RxNorm normalized name: amikacin 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amikacin 5 mg/kg
Trial: 11409580
Drug: amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: amikacin 15 mg/kg
Trial: 3237047
Drug: 0.10 g
RxNorm normalized name: RABBIT 0.10 g in 1 mL SUBCUTANEOUS INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 g NaHCO3·kg‐1 body weight (B)
Trial: 3237047
Drug: 0.15 g
RxNorm normalized name: AZELAIC ACID 0.15 g in 1 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 g NaHCO3·kg‐1 body weight (C)
Trial: 3237047
Drug: 0.20 g
RxNorm normalized name: ALBUMIN HUMAN 0.20 g in 1 mL INTRAVENOUS SOLUTION [FLEXBUMIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 g NaHCO3·kg‐1 body weight (D)
Trial: 23387320
Drug: Cognitive-behavioral nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral nutrition treatment
Trial: 9351763
Drug: Terbutaline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (0.25 mg)
Trial: 3621618
Drug: Dopamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (1 micrograms/kg/min by i.v. infusion)
Trial: 3621618
Drug: Dopamine (10(‐5)
RxNorm normalized name: dopamine hydrochloride 5 MG/ML
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (10(‐5) mol/l) in vitro
Trial: 3621618
Drug: Dopamine (10(‐9)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (10(‐9) mol/l‐10(‐5) mol/l) in vitro
Trial: 25782020
Drug: Pulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse therapy with methylprednisolone (500 mg daily intravenous for 3 days, followed by 1 mg/kg oral prednisolone for 11 days)
Trial: 25782020
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral prednisolone therapy (1 mg/kg oral prednisolone for 14 days)
Trial: 25782020
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (pulse therapy and traditional therapy)
Trial: 26677666
Drug: Qingre Yangyin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Yangyin Recipe (QRYYR), one dose per day in two portions, once in the morning and once in the evening.
Trial: 26677666
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group (Metformin).
Trial: 19650932
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 70 mg
Trial: 15722000
Drug: Functional Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Cognitive Behavioral Therapy (fCBT)
Trial: 11049785
Drug: High-dose vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vancomycin (2 g/day) combined with Saccharomyces boulardii (1 g/day for 28 days)
Trial: 11049785
Drug: High-dose vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vancomycin (2 g/day) combined with placebo
Trial: 15606696
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of cigarettes smoked daily
Trial: 29037578
Drug: Flagellin/F1/V vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flagellin/F1/V vaccine at 6 mcg
Trial: 29037578
Drug: Flagellin/F1/V vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flagellin/F1/V vaccine (all doses)
Trial: 29037578
Drug: Flagellin/F1/V vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flagellin/F1/V vaccine
Trial: 24756324
Drug: Diode 808-nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode 808-nm laser-assisted treatment
Trial: 24961183
Drug: MG +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG + MT
Trial: 1718119
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (dose of 10(-9) - 10(-11) mol)
Trial: 1718119
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (dose of 10(-10) mol)
Trial: 7183186
Drug: Nicotine administration/cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine administration/cigarette smoking
Trial: 20627197
Drug: Stannous chloride-containing
RxNorm normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stannous chloride-containing fluoride solution (800 ppm Sn(II), 500 ppm F, pH 4.5)
Trial: 20627197
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride solution (500 ppm F, pH 4.5)
Trial: 17717202
Drug: GW274150 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW274150 (90 mg)
Trial: 21940420
Drug: Adjuvant given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant given 2 days after vaccine (group T5)
Trial: 21940420
Drug: Adjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant concurrent with vaccine (group T4)
Trial: 8530624
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg rhIGF-I, sc, twice daily
Trial: 1673976
Drug: Astemizole, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole, 10 mg, daily for 2 weeks
Trial: 7102709
Drug: Acyclovir and
RxNorm normalized name: Acyclovir and hydrocortisone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir and dilute steroid drops
Trial: 24186848
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received repeated individual and group counseling on healthy lifestyles and guided antihypertensive therapy based on home BP measurements.
Trial: 19403551
Drug: Self- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self- and manual mobilization (1 hour twice a week for 8 weeks)
Trial: 17653649
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (0.64 ml) in a test meal (200 kcal per 200 ml)
Trial: 15621316
Drug: Daily cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cumulative load for females
Trial: 7661124
Drug: Supplemented men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented men (20 mg Fe/d)
Trial: 7661124
Drug: Supplemented women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented women (20 mg Fe/d)
Trial: 15914128
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 microg/DRSP 3 mg
Trial: 23117775
Drug: Daily multivitamin
RxNorm normalized name: DAILY MULTIVITAMIN TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multivitamin
Trial: 19921227
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (cannulated screw fixation)
Trial: 19921227
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (short arm cast)
Trial: 18940395
Drug: Plasma bFGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma bFGF immunoreactivity (bFGF‐IR) measured in pg/mL
Trial: 1310385
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin and oral acyclovir prophylaxis
Trial: 6436890
Drug: Nicotine 1.5
RxNorm normalized name: Nicotine 1.563 mg/hour prolonged-release transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 1.5 mg
Trial: 28761118
Drug: Bortezomib (BTZ)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (HDM, PAD arm)
Trial: 28761118
Drug: Classical cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical cytotoxic agents prior and thalidomide after HDM (VAD arm)
Trial: 28761118
Drug: Bortezomib (BTZ)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (BTZ) before and after high-dose melphalan and autologous stem cell transplantation (PAD arm)
Trial: 22859712
Drug: Valsartan (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (320 mg once daily)
Trial: 12471537
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole daily for long-term acid suppression
Trial: 10798755
Drug: Enteral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral supplementation (calorie‐dense enteral feed taken daily until transplantation)
Trial: 8973689
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-dose BCG (60 mg) and IFN alpha 2b (10, 30, 60, or 100 x 10(6) IU) given weekly for 6 weeks
Trial: 1358563
Drug: Oxatomide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (60 mg/day in a single evening administration)
Trial: 1358563
Drug: Disodium chromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium chromoglycate (DSCG, 2000 mg/day)
Trial: 19651449
Drug: Atorvastatin 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg/day and amlodipine 10mg/day
Trial: 19406402
Drug: Atorvastatin 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg/day
Trial: 19651449
Drug: Atorvastatin 20mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg/day and placebo
Trial: 28342534
Drug: Etanercept 50mg
RxNorm normalized name: ETANERCEPT 50MG/ML INJ SYRINGE
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept 50mg twice weekly
Trial: 28342534
Drug: Ixekizumab 160mg
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab 160mg starting dose followed by 80mg Q2W
Trial: 28342534
Drug: Ixekizumab 160mg
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab 160mg starting dose followed by 80mg Q4W
Trial: 16378695
Drug: l-5-Hydroxytryptophan (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-5-Hydroxytryptophan (200 mg)
Trial: 16378695
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg) and l-5-Hydroxytryptophan (200 mg)
Trial: 10877005
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg)
Trial: 11012562
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once daily for 7 days
Trial: 15729576
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin detemir
Trial: 8818852
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg/day orally once daily for 3 days
Trial: 8818852
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg orally twice daily for 10 days
Trial: 7078714
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose diazepam (150-200 mg/day)
Trial: 7078714
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose diazepam (150-200 mg/day) with naloxone (30 mg i.v.)
Trial: 16403108
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cream (placebo)
Trial: 10449279
Drug: Twice-daily didanosine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Trial: 7605759
Drug: Alkalinized mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized mepivacaine (1 mL sodium bicarbonate per 10 mL mepivacaine)
Trial: 20571433
Drug: paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paroxetine 20 mg/d
Trial: 17327187
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine gluconate surgical skin preparation (SP)
Trial: 11865964
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg bosentan tablet (with food)
Trial: 11865964
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of 62.5 mg bosentan (with food)
Trial: 11865964
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of bosentan (without food)
Trial: 7555159
Drug: Anistreplase (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anistreplase (30 U/5 min) + heparin
Trial: 7555159
Drug: Heparin-only therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-only therapy
Trial: 21519221
Drug: New dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New dose regimen of artesunate and amodiaquine (NDRAA)
Trial: 19650425
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (0.05-1.5 W/cm2, 1 MHz frequency, 3-9 minutes per session, 10 sessions total)
Trial: 19650425
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (0.5-1.5 W/cm2, 4-9 minutes per session)
Trial: 9814494
Drug: Propranolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol monotherapy after 7 days
Trial: 7897129
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 10)
Trial: 27785736
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin administered before a meal (30 min before a meal)
Trial: 27785736
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin administered before sleep
Trial: 27785736
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin administered during a meal
Trial: 27785736
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin administered after a meal
Trial: 25423326
Drug: Soy dietary
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy dietary supplement (90 mg of isoflavone)
Trial: 21712835
Drug: Inulin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (24 g)
Trial: 26178580
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (5000 IU) + Calcium (600 mg)
Trial: 22015095
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg per day) in severe urticaria subgroup
Trial: 10959805
Drug: 6 or
RxNorm normalized name: Serc-16 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 or 9 million units (MU) interferon three times a week for 6 months (total dose: 468 or 702 MU)
Trial: 10959805
Drug: 6MU of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MU of IFN over 6 months (total dose 564 MU)
Trial: 8622389
Drug: Bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200 mg three times daily)
Trial: 8169401
Drug: Zidovudine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (200 mg every 8 h) and fluconazole (400 mg daily) for 7 days
Trial: 2467134
Drug: Amlodipine 2.5-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5-10.0 mg daily
Trial: 27442085
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus 1.2% Atorvastatin (ATV)
Trial: 25706516
Drug: AOK-proReha treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOK-proReha treatment approach
Trial: 24717954
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Trial: 18596271
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1 mg of epinephrine and 40 IU of vasopressin
Trial: 9878938
Drug: Dalteparin 120
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 120 IU/kg body weight twice daily
Trial: 9878938
Drug: Dalteparin 7500
RxNorm normalized name: dalteparin 7500 intl units/0.3 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 7500 IU once daily (fixed dose)
Trial: 9878938
Drug: Weight-adjusted treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted treatment
Trial: 9878938
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose treatment
Trial: 31499373
Drug: Acute phase
RxNorm normalized name: Acute phase reactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute phase treatment
Trial: 9878938
Drug: Fixed-dose treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose treatment
Trial: 4012191
Drug: Flunarizine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (15 mg nocte)
Trial: 26768928
Drug: Saline (control)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (control) administered in a similar manner to Dex
Trial: 29961346
Drug: Client-centred activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centred activities of daily living (CADL) intervention
Trial: 22678673
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of akatinol memantine 20 mg in the morning
Trial: 16383037
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days (T group)
Trial: 20104197
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (C group)
Trial: 7593517
Drug: Nafarelin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin (200 micrograms twice daily as a nasal spray)
Trial: 3833371
Drug: Liquid capsules
RxNorm normalized name: Calcium Liquid Capsules with Vitamin D
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid capsules
Trial: 29521723
Drug: Mechanical Lithotripsy
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical Lithotripsy (ML)
Trial: 26885787
Drug: Dapsone 5%
RxNorm normalized name: DAPSONE 5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 5% gel (twice daily) with oral doxycycline hyclate 100mg (once daily) for 12 weeks, followed by dapsone 5% gel (twice daily) for 12 weeks